Cancer risk assessment, indicators, and guidelines for polycyclic aromatic hydrocarbons in the ambient air.

CE Boström, P Gerde, A Hanberg… - Environmental …, 2002 - ehp.niehs.nih.gov
Polycyclic aromatic hydrocarbons (PAHs) are formed during incomplete combustion.
Domestic wood burning and road traffic are the major sources of PAHs in Sweden. In …

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

GK Dresser, JD Spence, DG Bailey - Clinical pharmacokinetics, 2000 - Springer
Drug interactions occur when the efficacy or toxicity of a medication is changed by
administration of another substance. Pharmacokinetic interactions often occur as a result of …

Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes

JM Borghardt, C Kloft, A Sharma - Canadian respiratory journal, 2018 - Wiley Online Library
The inhalation route is frequently used to administer drugs for the management of
respiratory diseases such as asthma or chronic obstructive pulmonary disease. Compared …

Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts

X Ding, LS Kaminsky - Annual review of pharmacology and …, 2003 - annualreviews.org
Cytochrome P450 (CYP) enzymes in extrahepatic tissues often play a dominant role in
target tissue metabolic activation of xenobiotic compounds. They may also determine drug …

Lipid nanoparticles as delivery vehicles for inhaled therapeutics

EWX Leong, R Ge - Biomedicines, 2022 - mdpi.com
Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery.
With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …

Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung

J Hukkanen, O Pelkonen, J Hakkola… - Critical reviews in …, 2002 - Taylor & Francis
Pathogenesis of lung diseases, such as lung cancer and chronic obstructive pulmonary
disease, is tightly linked to exposure to environmental chemicals, most notably tobacco …

Role of P‐glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

VJ Wacher, JA Silverman, Y Zhang… - Journal of …, 1998 - Wiley Online Library
Abstract Cytochrome P450 3A4 (CYP3A4), the major phase I drug metabolizing enzyme in
humans, and the MDR1 gene product P‐glycoprotein (P‐gp) are present at high …

Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues

P Pavek, Z Dvorak - Current drug metabolism, 2008 - ingentaconnect.com
Numerous members of the cytochrome P450 (CYP) superfamily are induced after exposure
to a variety of xenobiotics in human liver. We have gained considerable mechanistic insights …

Pulmonary drug metabolism, clearance, and absorption

B Olsson, E Bondesson, L Borgström… - … pulmonary drug delivery, 2011 - Springer
Delivering therapeutic agents to the lungs requires a deep understanding of the kinetics and
dynamics of drugs in this biologically and physiologically complex system. In this chapter …

Genetic variability in CYP3A5 and its possible consequences

HG **e, AJJ Wood, RB Kim, CM Stein… - …, 2004 - Taylor & Francis
The cytochrome P450 3A (CYP3A) subfamily members are the most abundant and important
drug-metabolizing enzymes in humans, and wide interindividual variability in CYP3A …